Plasma Cell Neoplasms (Including Multiple Myeloma), part 2

Radiation therapy to the tumor and nearby lymph nodes.

Sources: Radiation therapy · tumor · lymph nodes

Surgery, usually followed by radiation therapy.

Sources: Surgery

Watchful waiting after initial treatment, followed by radiation therapy, surgery, or chemotherapy if the tumor grows or causes signs or symptoms.

Sources: Watchful waiting · initial treatment · chemotherapy · signs · symptoms

Younger, fit patients who are eligible for a stem cell transplant.

Sources: stem cell transplant

Older, unfit patients who are not eligible for a stem cell transplant.

Induction therapy: This is the first phase of treatment. Its goal is to reduce the amount of disease, and may include one or more of the following:

Sources: Induction therapy

Induction therapy: This is the first phase of treatment. Its goal is to reduce the amount of disease, and may include one or more of the following:

For younger, fit patients (eligible for a transplant):

Induction therapy: This is the first phase of treatment. Its goal is to reduce the amount of disease, and may include one or more of the following: › For younger, fit patients (eligible for a transplant):

Chemotherapy.

Sources: Chemotherapy

Targeted therapy with a proteasome inhibitor (bortezomib) and a monoclonal antibody (daratumumab).

Sources: Targeted therapy · proteasome inhibitor · bortezomib · monoclonal antibody · daratumumab

Immunotherapy (lenalidomide).

Sources: Immunotherapy · lenalidomide

Corticosteroid therapy (dexamethasone).

Sources: Corticosteroid · dexamethasone

Induction therapy: This is the first phase of treatment. Its goal is to reduce the amount of disease, and may include one or more of the following:

For older, unfit patients (not eligible for a transplant):

Induction therapy: This is the first phase of treatment. Its goal is to reduce the amount of disease, and may include one or more of the following: › For older, unfit patients (not eligible for a transplant):

Chemotherapy.

Targeted therapy with a proteasome inhibitor (bortezomib or carfilzomib) or a monoclonal antibody (daratumumab).

Sources: carfilzomib

Immunotherapy (lenalidomide).

Corticosteroid therapy (dexamethasone).

Consolidation therapy: This is the second phase of treatment. Treatment in the consolidation phase is to kill any remaining cancer cells. High-dose chemotherapy is followed by either:

Sources: Consolidation therapy · cancer · cells · High-dose chemotherapy

Consolidation therapy: This is the second phase of treatment. Treatment in the consolidation phase is to kill any remaining cancer cells. High-dose chemotherapy is followed by either:

one autologous stem cell transplant, in which the patient's stem cells from the blood or bone marrow are used; or

Sources: autologous stem cell transplant · stem cells · blood · bone marrow

two autologous stem cell transplants followed by an autologous or allogeneic stem cell transplant, in which the patient receives stem cells from the blood or bone marrow of a donor; or

Sources: allogeneic stem cell transplant · donor

one allogeneic stem cell transplant.

Maintenance therapy: After the initial treatment, maintenance therapy is often given to help keep the disease in remission for a longer time. Several types of treatment are being studied for this use, including the following:

Sources: Maintenance therapy · initial treatment · remission

Maintenance therapy: After the initial treatment, maintenance therapy is often given to help keep the disease in remission for a longer time. Several types of treatment are being studied for this use, including the following:

Chemotherapy.

Immunotherapy (lenalidomide).

Corticosteroid therapy (prednisone or dexamethasone).

Sources: prednisone

Targeted therapy with a proteasome inhibitor (bortezomib or ixazomib) or a monoclonal antibody (daratumumab).

Sources: ixazomib

Watchful waiting for patients whose disease is stable.

Sources: Watchful waiting · stable

A different treatment than treatment already given, for patients whose tumor kept growing during treatment. See Multiple Myeloma treatment options.

Sources: tumor · Multiple Myeloma

The same drugs used before the relapse may be used if the relapse occurs one or more years after initial treatment. See Multiple Myeloma treatment options.

Sources: drugs · Multiple Myeloma

Targeted therapy with monoclonal antibodies (daratumumab, elotuzumab, or isatuximab).

Sources: Targeted therapy · monoclonal antibodies · daratumumab · elotuzumab · isatuximab

Targeted therapy with proteasome inhibitors (bortezomib, carfilzomib, or ixazomib).

Sources: proteasome inhibitors · bortezomib · carfilzomib · ixazomib

Immunotherapy (pomalidomide, lenalidomide, or thalidomide).

Sources: Immunotherapy · pomalidomide · lenalidomide · thalidomide

Chemotherapy.

Sources: Chemotherapy

Corticosteroid therapy.

Sources: Corticosteroid

A clinical trial of CAR T-cell therapy.

Sources: clinical trial · CAR T-cell therapy

A clinical trial of targeted therapy with a small molecule inhibitor (selinexor) and corticosteroid therapy.

Sources: selinexor

A clinical trial of targeted therapy with a BCL2 inhibitor (venetoclax).

Sources: BCL2 · venetoclax